Request Your Free White Paper Now:

"Employing a Functional Service Provider (FSP) partnerships model in non-footprint countries: trends, challenges and solutions"

Meeting the demands of a changing clinical research landscape

As clinical trials become more complex, many drug developers have turned to outsourcing models to keep up with the demands of the industry. Among these demands is the pressure to maintain a broader global presence. Geographically expanding operations can allow drug developers to reach a more diverse clinical trial population, access in-country regulatory expertise, proactively mitigate risk and overcome competition for sites and participants as the research landscape becomes more crowded. However, initiating and maintaining a substantial presence in every country to conduct research is simply unfeasible for most pharma and biotech organizations. Learn more about how this issue might be approached via a tailored FSP model.

Did you know? Leveraging an FSP model to support non-footprint countries provides greater resource flexibility and access to specific expertise not readily available in-house. A recent survey of biopharma leaders conducted by the PPD™ clinical research business of Thermo Fisher Scientific revealed an increase in FSP outsourcing over the past two years, with 41% of respondents reporting increased use of FSP models.

Would you like to discuss your Functional Service Provider (FSP) outsourcing needs with an industry specialist?

Offered Free by: PPD
See All Resources from: PPD